BiotechTube

SHR4640 + Allopurinol

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Gout

Conditions

Gout

Trial Timeline

Jun 15, 2021 → Aug 23, 2024

NCT ID
NCT04956432

About SHR4640 + Allopurinol

SHR4640 + Allopurinol is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Gout. The current trial status is completed. This product is registered under clinical trial identifier NCT04956432. Target conditions include Gout.

What happened to similar drugs?

12 of 20 similar drugs in Gout were approved

Approved (12) Terminated (3) Active (7)
✅LumiracoxibNovartisApproved
✅Pegloticase + MethotrexateAmgenApproved
✅Pegloticase + Methotrexate (MTX)AmgenApproved
✅Pegloticase + Methotrexate (MTX) + Standard Gout Flare Prophylaxis + Infusion Reaction (IR) ProphylaxisAmgenApproved
✅Pegloticase + methotrexate + placebo + gout flare prophylaxis regimen + fexofenadine + acetaminophen + methylprednisoloneAmgenApproved
✅Etanercept + Triamcinolone AcetonideAmgenApproved
✅PegloticaseAmgenApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04956432Phase 3Completed

Competing Products

20 competing products in Gout

See all competitors
ProductCompanyStageHype Score
febuxostat + AllopurinolAstellas PharmaPhase 3
40
Dotinurad + FebuxostatEisaiPhase 3
40
BaricitinibEli LillyPhase 2
35
HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tabletsJiangsu Hengrui MedicinePhase 1
25
SHR4640 tablet + SHR4640 tablet + febuxostat tablet + SHR4640 placebo tabletJiangsu Hengrui MedicinePhase 2
31
repaglinide; midazolam; SHR4640 + repaglinide; midazolam; SHR4640; SHR4640 placebo + repaglinide; midazolam; SHR4640 placeboJiangsu Hengrui MedicinePhase 1
29
SHR4640 + placeboJiangsu Hengrui MedicinePhase 1
29
SHR4640 dose1 + SHR4640 dose2 + Placebo oral tablet + Allopurinol 300 MGJiangsu Hengrui MedicinePhase 3
40
Colchicine + Febuxostat + SHR4640Jiangsu Hengrui MedicinePhase 1
29
SHR4640 ；Febuxostat + SHR4640 ; Febuxostat + SHR4640 + SHR4640 + FebuxostatJiangsu Hengrui MedicinePhase 2
42
SHR4640Jiangsu Hengrui MedicinePhase 1
25
HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tabletsJiangsu Hengrui MedicinePhase 3
47
HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tabletsJiangsu Hengrui MedicinePhase 3
40
SHR4640 + PlaceboJiangsu Hengrui MedicinePhase 1
29
Zurampic® + Control group: xanthine oxidase inhibitor monotherapyAstraZenecaPre-clinical
18
Risk of selected safety eventsAstraZenecaPre-clinical
26
AZD6140 + Placebo to match AZD6140AstraZenecaPhase 1
29
RDEA3170 + Allopurinol + PlaceboAstraZenecaPhase 2
35
RDEA3170 + Febuxostat + BenzbromaroneAstraZenecaPhase 1/2
32
Canakinumab pre-filled syringe + Canakinumab lyophilized powder + Triamcinolone Acetonide + PlaceboNovartisPhase 3
40